Detalhe da pesquisa
1.
Early Use of Biologics Reduces Healthcare Costs in Crohn's Disease: Results from a United States Population-Based Cohort.
Dig Dis Sci
; 69(1): 45-55, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36920668
2.
Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Crohn's Disease in US and Europe: Results from the Cross-Sectional CONFIDE Study.
Dig Dis Sci
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700629
3.
P028 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Experience of Ulcerative Colitis Symptoms.
Am J Gastroenterol
; 116(Suppl 1): S7, 2021 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37461947
4.
Patient Perspectives of Bowel Urgency and Bowel Urgency-Related Accidents in Ulcerative Colitis and Crohn's Disease.
Inflamm Bowel Dis
; 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513272
5.
Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Program.
J Crohns Colitis
; 2024 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38869019
6.
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Inflamm Bowel Dis
; 2024 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38459910
7.
Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission.
Crohns Colitis 360
; 5(1): otac044, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36777368
8.
Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe.
Curr Med Res Opin
; 39(9): 1205-1214, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37545338
9.
Rectal Urgency Among Patients With Ulcerative Colitis or Crohn's Disease: Analyses from a Global Survey.
Crohns Colitis 360
; 5(4): otad052, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37928613
10.
The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis.
Inflamm Bowel Dis
; 2023 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37603837
11.
Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies.
Crohns Colitis 360
; 5(4): otad070, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-38034882